Showing results (41-50 of 67) with videos related to
Sort By:
Pageof 7
Scientific Reports|November 12, 2022
Ensemble machine learning identifies genetic loci associated with future worsening of disability in people with multiple sclerosisValery Fuh-Ngwa, Yuan Zhou, Phillip E Melton, et al.Neurology(R) Neuroimmunology & Neuroinflammation|December 4, 2020
Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disordersSimon Rinaldi, Alexander Davies, Janev Fehmi, et al.Neurology|December 14, 2020
Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic ReviewViktoria Papp, Melinda Magyari, Orhan Aktas, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|May 6, 2023
A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort studyAlice M Saul, Bruce V Taylor, Leigh Blizzard, et al.Frontiers in Neurology|July 17, 2020
Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence WorldwideJyh Yung Hor, Nasrin Asgari, Ichiro Nakashima, et al.Environmental Epigenetics|May 27, 2026
DNA methylation mediates the multiple sclerosis onset risk associated with HHV-6 DNA positivityAlex Eisner, Steve Simpson-Yap, Daniel J Park, et al.Plos One|December 15, 2010
A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosisCarlos Riveros, Drew Mellor, Kaushal S Gandhi, et al.Journal of Neurology|July 3, 2024
Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysisSimon Arnett, Sin Hong Chew, Unnah Leitner, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 14, 2024
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapseBenjamin P Trewin, Russell C Dale, Jessica Qiu, et al.CNS Drugs|January 10, 2025
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic ApproachVivien Li, Fiona C McKay, David C Tscharke, et al.Pageof 7